• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

一种新型缓释片给药后茶碱的处置及临床药代动力学

Disposition and clinical pharmacokinetics of theophylline after administration of a new sustained release tablet.

作者信息

Jonkman J H, Berg W C, de Vries K, de Zeeuw R A, Schoenmaker R, Grimberg N

出版信息

Eur J Clin Pharmacol. 1981;21(1):39-44. doi: 10.1007/BF00609586.

DOI:10.1007/BF00609586
PMID:7333345
Abstract

The systemic disposition of theophylline after taking a new, sustained release tablet (Theolair Retard 250 mg, Theolair S.R., Riker Laboratories) has been studied in 8 hospitalized patients. Absolute bioavailability was determined from the ratios of the areas under the serum concentration-time curves after intake of the tablet and after intravenous infusion of aminophylline in the same patient. The absolute bioavailability of Theolair Retard 250 mg was 110.9 +/- 20.8% (mean +/-SD). Maximal serum concentrations were reached after 7.3 +/- 3.5 h, the large intersubject variation being due to differences in gastric emptying time. The tablets appear to release theophylline slowly in acid conditions, but more rapidly in an alkaline medium. Invasion was found to be either monophasic with a rate constant of about 0.8 h-1 (intestine), or biphasic with rate constants of 0.2 h-1 (stomach) and 0.8 h-1 (intestine). The peak levels accounted for 7.9 +/- 2.2 mg . 1-1. The profiles of the serum concentration-time curves were such that the concentrations remained above 80% of cmax for 6.5 +/- 3.3 h. The relevant pharmacokinetic parameters (half-life of elimination, total body clearance and volume of distribution) were determined and were used to calculate the individual dosage regimens required to obtain therapeutic serum concentrations. The optimal dosing interval to obtain an average steady state serum concentration of 12.5 mg . l-1 was 9.8 +/- 3.1 h.

摘要

在8名住院患者中研究了服用新型缓释片(Theolair Retard 250 mg,Theolair S.R.,莱克实验室)后茶碱的全身处置情况。通过同一患者服用该片剂后与静脉输注氨茶碱后血清浓度-时间曲线下面积之比来确定绝对生物利用度。Theolair Retard 250 mg的绝对生物利用度为110.9±20.8%(平均值±标准差)。最大血清浓度在7.3±3.5小时后达到,个体间差异较大是由于胃排空时间不同。该片剂在酸性条件下似乎缓慢释放茶碱,但在碱性介质中释放更快。发现吸收呈单相,肠道的速率常数约为0.8 h⁻¹,或呈双相,胃的速率常数为0.2 h⁻¹,肠道的速率常数为0.8 h⁻¹。峰值水平为7.9±2.2 mg·L⁻¹。血清浓度-时间曲线的特征是浓度在6.5±3.3小时内保持在cmax的80%以上。测定了相关的药代动力学参数(消除半衰期、全身清除率和分布容积),并用于计算获得治疗性血清浓度所需的个体给药方案。为使平均稳态血清浓度达到12.5 mg·L⁻¹的最佳给药间隔为9.8±3.1小时。

相似文献

1
Disposition and clinical pharmacokinetics of theophylline after administration of a new sustained release tablet.一种新型缓释片给药后茶碱的处置及临床药代动力学
Eur J Clin Pharmacol. 1981;21(1):39-44. doi: 10.1007/BF00609586.
2
Disposition and clinical pharmacokinetics of microcrystalline theophylline.微晶型茶碱的处置与临床药代动力学
Eur J Clin Pharmacol. 1980 May;17(5):379-84. doi: 10.1007/BF00558452.
3
Pharmacokinetics and pharmacodynamics of a short- and long-acting theophylline medication (theolair and Theolair retard) in normals and asthmatics. Part I: pharmacokinetics.短效和长效茶碱药物(Theolair和Theolair缓释片)在正常人和哮喘患者中的药代动力学和药效学。第一部分:药代动力学。
Int J Clin Pharmacol Ther Toxicol. 1983 Jun;21(6):287-91.
4
Bioavailability of theophylline from a sustained-release aminophylline formulation (Euphyllin retard tablets)--plasma levels after single and multiple oral doses.来自缓释氨茶碱制剂(优喘平缓释片)的茶碱生物利用度——单次和多次口服给药后的血浆水平
Int J Clin Pharmacol Ther Toxicol. 1981 May;19(5):223-7.
5
Chronopharmacokinetics of theophylline after sustained release and intravenous administration to adults.
Eur J Clin Pharmacol. 1984;26(2):215-22. doi: 10.1007/BF00630288.
6
Greatly enhanced bioavailability of theophylline on postprandial administration of a sustained release tablet.茶碱缓释片餐后给药时生物利用度大幅提高。
Eur J Clin Pharmacol. 1983;24(6):761-7. doi: 10.1007/BF00607084.
7
Pharmacokinetics and pharmacodynamics of three sustained-release theophylline preparations (350 mg Theograd, 350 mg Theolair Retard and 300 mg Theodur) in steady state in healthy volunteers and asthmatics--Part I: Theophylline plasma levels.
Int J Clin Pharmacol Ther Toxicol. 1984 Aug;22(8):423-9.
8
The absolute bioavailability of a new pediatric sustained release theophylline tablet, when given as whole or divided tablets.一种新型儿科缓释茶碱片以整片或分服形式给药时的绝对生物利用度。
Int J Clin Pharmacol Ther Toxicol. 1984 Sep;22(9):506-10.
9
Bioavailability and pharmacokinetics of theophylline in plain uncoated and sustained-release dosage forms in relation to smoking habit. I. Single dose study.茶碱普通无包衣剂型和缓释剂型的生物利用度及药代动力学与吸烟习惯的关系。I. 单剂量研究。
Eur J Clin Pharmacol. 1983;24(1):79-87. doi: 10.1007/BF00613931.
10
[Bioavailability of 3 theophylline delayed-release preparations. Comparison of theophylline concentrations in the serum and saliva in the steady state].
Schweiz Med Wochenschr. 1982 Nov 20;112(47):1702-10.

引用本文的文献

1
Metrics for the evaluation of bioequivalence of modified-release formulations.用于评价缓释制剂生物等效性的指标。
AAPS J. 2012 Dec;14(4):813-9. doi: 10.1208/s12248-012-9396-8. Epub 2012 Aug 22.
2
Bioavailability and pharmacokinetics of theophylline in plain uncoated and sustained-release dosage forms in relation to smoking habit. I. Single dose study.茶碱普通无包衣剂型和缓释剂型的生物利用度及药代动力学与吸烟习惯的关系。I. 单剂量研究。
Eur J Clin Pharmacol. 1983;24(1):79-87. doi: 10.1007/BF00613931.
3
Bioavailability and diurnal variation in absorption of sustained release theophylline in asthmatic children.

本文引用的文献

1
Disposition and clinical pharmacokinetics of microcrystalline theophylline.微晶型茶碱的处置与临床药代动力学
Eur J Clin Pharmacol. 1980 May;17(5):379-84. doi: 10.1007/BF00558452.
2
Serum theophylline levels in adult asthmatics: comparison of oral sustained-release and microcrystalline preparations.
N Z Med J. 1980 Sep 10;92(667):196-8.
3
Pharmacokinetics of Nuelin-SR 250 mg in asthmatic children: a new sustained-release theophylline.250毫克纽林缓释片(Nuelin-SR)在哮喘儿童中的药代动力学:一种新型缓释茶碱
哮喘儿童中缓释型茶碱的生物利用度及吸收的昼夜变化
Eur J Clin Pharmacol. 1983;25(5):667-72. doi: 10.1007/BF00542356.
4
A "once a day administration" sustained-release theophylline formulation: disposition and pharmacokinetics.一种“每日一次给药”的缓释茶碱制剂:处置与药代动力学。
Eur J Clin Pharmacol. 1984;27(3):325-8. doi: 10.1007/BF00542169.
5
A clinical and pharmacokinetic basis for the selection and use of slow release theophylline products.缓释型茶碱产品选用的临床及药代动力学依据
Clin Pharmacokinet. 1984 Mar-Apr;9(2):95-135. doi: 10.2165/00003088-198409020-00001.
6
Food interactions with sustained-release theophylline preparations. A review.食物与缓释茶碱制剂的相互作用。综述。
Clin Pharmacokinet. 1989 Mar;16(3):162-79. doi: 10.2165/00003088-198916030-00003.
7
Pharmacokinetic characterization of controlled-release formulations.
Eur J Drug Metab Pharmacokinet. 1990 Apr-Jun;15(2):173-81. doi: 10.1007/BF03190201.
8
Controversies in bioequivalence studies.生物等效性研究中的争议
Clin Pharmacokinet. 1992 Apr;22(4):247-53. doi: 10.2165/00003088-199222040-00001.
N Z Med J. 1980 Aug 13;92(665):91-3.
4
Comparison of Theolair SR and Theo-Dur tablets.Theolair SR片与茶喘平缓释片的比较。
Ann Allergy. 1979 Oct;43(4):220-2.
5
Simultaneous use of rapidly absorbed and sustained release theophylline preparations in children.儿童同时使用快速吸收型和缓释型茶碱制剂。
Ann Allergy. 1979 Oct;43(4):217-9.
6
Comparison of plasma theophylline concentrations achieved with a microcrystalline formulation and a sustained release preparation of theophylline [proceedings].微晶制剂与茶碱缓释制剂所达到的血浆茶碱浓度比较[会议论文集]
Br J Clin Pharmacol. 1979 Apr;7(4):425P. doi: 10.1111/j.1365-2125.1979.tb00970.x.
7
Monitoring serum theophylline levels.监测血清茶碱水平。
Clin Pharmacokinet. 1978 Jul-Aug;3(4):294-312. doi: 10.2165/00003088-197803040-00003.
8
Clinical pharmacokinetics of theophylline.茶碱的临床药代动力学
Clin Pharmacokinet. 1978 Jul-Aug;3(4):267-93. doi: 10.2165/00003088-197803040-00002.